Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-260-7120
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees88
Next Earnings Date8/5/2019 (Estimated)
OptionableOptionable
Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions
What is Iovance Biotherapeutics' stock symbol?
Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."
How were Iovance Biotherapeutics' earnings last quarter?
Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced its earnings results on Tuesday, May, 7th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.01. View Iovance Biotherapeutics' Earnings History.
When is Iovance Biotherapeutics' next earnings date?
What price target have analysts set for IOVA?
9 brokers have issued 12 month price targets for Iovance Biotherapeutics' shares. Their forecasts range from $20.00 to $34.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $27.00 in the next year. This suggests a possible upside of 56.5% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.
What is the consensus analysts' recommendation for Iovance Biotherapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.
What are Wall Street analysts saying about Iovance Biotherapeutics stock?
Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and price target of $26. Our target is based on our clinical net present value (NPV) model, which derives its primary value from LN-144 for metastatic melanoma currently. This model allows us to flex multiple assumptions affecting Iovance Biotherapeutics, Inc. May 23, 2019 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2a drug’s potential commercial profile." (5/23/2019)
- 2. Chardan Capital analysts commented, "We expect more visibility as Iovance plans to engage with the FDA in 2019 to define a regulatory path for LN-145 in 2nd-line cervical cancer, for which it recently received Fast Track Designation. We expect Iovance will be able to advance this program relatively quickly based on learnings from lifileucel. We expect to hear more on manufacturing and preclinical programs in 2019, as the company’s focus expands beyond the current phase II trials. Iovance is in the late stages of site selection for a manufacturing facility and expects to provide updates in 2Q19. To us, establishing an internal manufacturing facility will be a key step in commercial execution. Iovance is also planning to file an IND for peripheral blood lymphocytes (PBL) in hematological malignancies in 2019. We understand this program uses a distinct and shorter manufacturing process." (2/28/2019)
- 3. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/15/2019)
Has Iovance Biotherapeutics been receiving favorable news coverage?
Press coverage about IOVA stock has been trending extremely negative this week, InfoTrie reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iovance Biotherapeutics earned a news sentiment score of -4.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Iovance Biotherapeutics' key competitors?
Some companies that are related to Iovance Biotherapeutics include BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI) and Audentes Therapeutics (BOLD).
What other stocks do shareholders of Iovance Biotherapeutics own?
Who are Iovance Biotherapeutics' key executives?
Iovance Biotherapeutics' management team includes the folowing people:
- Dr. Maria Fardis, CEO, Pres & Director (Age 51)
- Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
- Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
- Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
- Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)
Who are Iovance Biotherapeutics' major shareholders?
Iovance Biotherapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (9.91%), BlackRock Inc. (7.15%), Broadfin Capital LLC (3.50%), Victory Capital Management Inc. (2.00%), Geode Capital Management LLC (1.19%) and Northern Trust Corp (1.12%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.
Which institutional investors are selling Iovance Biotherapeutics stock?
IOVA stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Schonfeld Strategic Advisors LLC, Victory Capital Management Inc., Rhenman & Partners Asset Management AB, Goldman Sachs Group Inc., Citigroup Inc., FMR LLC and Prosight Management LP. View Insider Buying and Selling for Iovance Biotherapeutics.
Which institutional investors are buying Iovance Biotherapeutics stock?
IOVA stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Osterweis Capital Management Inc., Marshall Wace North America L.P., Wells Fargo & Company MN, Fosun International Ltd and Geode Capital Management LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.
How do I buy shares of Iovance Biotherapeutics?
Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iovance Biotherapeutics' stock price today?
One share of IOVA stock can currently be purchased for approximately $17.25.
How big of a company is Iovance Biotherapeutics?
Iovance Biotherapeutics has a market capitalization of $2.13 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.
What is Iovance Biotherapeutics' official website?
How can I contact Iovance Biotherapeutics?
Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]
MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
